Exact Sciences (EXAS) 7th Annual Healthcare Symposium summary

Key industry challenges and trends

• Aging populations are driving increased healthcare spending, projected to reach 20% of U.S. GDP by the early 2030s, with cancer incidence and mortality expected to rise significantly by 2050.

• Access to innovative diagnostics and vaccines remains uneven globally, with higher-income populations consuming a disproportionate share.

• Longevity pressures, technology advancements, and incentive alignment across the healthcare value chain are central challenges.

Multi-cancer early detection (MCED) strategies

• Companies are pursuing different MCED approaches: some focus on single-cancer tests before expanding, while others develop broad multi-cancer tests from inception.

• MCED technologies leverage blood-based biomarkers, with some tests detecting shared cancer signals and others targeting specific indications.

• Partnerships among diagnostic firms, academic centers, and healthcare networks are key to expanding access and evidence generation.

• MCED is positioned as complementary to standard-of-care screenings, not a replacement.

Partnerships and access

• Broad networks and infrastructure, such as those of major diagnostic providers, are leveraged to improve patient access and adherence to screening.

• Collaboration with pharma, payers, and service providers is essential for evidence generation, reimbursement, and patient navigation.

• Innovative access models and risk triage tests are being developed to identify at-risk populations and guide follow-up care.